Publications by authors named "C Schnopp"
Atopic dermatitis (AD) is the most common skin disease in infants and children with a prevalence of 10% in the first two years of life. In this age group up to 15% are severely affected. "Children are not little adults" - this applies in particular to infants with severe atopic dermatitis.
View Article and Find Full Text PDFArticle Synopsis
- Treatment options for young children with severe atopic dermatitis (AD) are limited, but dupilumab is the first approved systemic treatment for infants and children under 6 years in the EU.
- In a study involving 125 children aged 6 months to 5 years, those receiving dupilumab showed significantly better skin improvements and reduced symptoms compared to those on placebo, especially by week 16.
- The safety profile of dupilumab was comparable to placebo, with no serious side effects related to the drug reported, indicating it is a viable option for managing severe AD in this age group.